Abstract
Already in 1943, Beeson observed a connection between the transfusion of blood products and the emergence of hepatitis [1]. Jaundice developed in 7 patients 1–4 months after the administration of whole blood or plasma. Further reports on the development of hepatitis in hemophilic patients were published in the mid-70s [2, 3, 4]. Today it is generally accepted that the hepatitis C virus causes the majority of cases of post-transfusion hepatitis in the western world. It is responsible for most of the chronic liver disorders observed in hemophilic patients treated with clotting factor concentrates. The hepatitis C infection can be associated with replacement therapy involving clotting factor concentrates applied in the early 1970s [2, 5, 6].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beeson PB. Jaundice occuring one to four months after transfusion of blood or plasma: report of seven cases. J Am Med Assoc 1943; 121: 1332–4
Kasper CK, Kipnis SA. Hepatitis and clotting-factor concentrates. JAMA 1972; 221: 510
Mannucci PM, Capitanio A, del Nino E, Colombo M, Pareti F, Ruggeri ZM. A symptomatic liver disease in haemophiliacs. J Clin Path 1975; 28: 620–4
Schimpf K, Zimmermann K. Hepatitishäufigkeit, serologische Befunde und Leberhistologie nach Therapie schwerer hämorrhagischer Diathesen mit Gerinnungsfaktorenkonzentraten. In: Fibrinogen, Fibrin, and Fibrin Glue. Side effects of the therapy with clottimg factor concentrates. Schimpf K Ed, Schattauer Verlag 1980; 299–308
Hasiba UW, Spero JA, Lewis JH. Chronic liver dysfunction in multitransfused haemo-philiacs. Transfusion 1977; 17: 490
Preston FE, Jarvis LM, Makris M, Philp L, Underwood JCE, Ludlam CA, Simmonds P. Heterogeneity of hepatitis C virus genotypes in haemophilia: relationship with chronic liver disease. Blood 1995; 85: 1259–62
Makris M, Preston FE, Triger DR, Underwood JC. The natural history of chronic liver disease in haemophilia: more rapid progression relates to age and mild disease (abstract). Br. J Haematol 1992; 81(Suppl. 1): 72
Zeuzem S, Roth WK, Herrmann G. Virushepatitis C. Z Gastroenterol 1995; 33: 117–32
Simonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap Pl, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a serie of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391
Makris M, Preston M, Triger DR,Underwood JCE, Westlake L, Adelman MI. A randomized controlled trial of recombinant interferon-a in chronic hepatitis C in hemophiliacs. Blood 1991; 78: 1672–7
Laursen AL, Scheibel E, Ingerslev J, Clausen NC, Wantzin P, Oestergaard L, Schou G, Black FT, Krosgaard K. Alpha interferon therapy in Danish hemophilic patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon-alpha-2b treatment. Haemophilia 1998; 4: 25–32
Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shifmann ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493–1499
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998, 339: 1485–1492
Palmer Smith J. Treatment of chronic hepatitis C with amantadine Dig Dis and Sciences 1997; 42: 1681–1687
Zeuzem S, Feinman SV, Rasenack J, Heathcote E,Lai MY, Gane E, et al. Peginterferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–1672. Abstract
Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology. 2001 Aug; 34(2): 395–403. Abstract
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965. Abstract.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Zimmermann, R., Huth-Kühne, A., Lages, P., Kallinowski, B. (2004). Treatment with Interferon Alpha-2a in Patients with Hepatitis C and Hemophilia. In: Scharrer, I., Schramm, W. (eds) 33rd Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18260-0_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-18260-0_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-00902-3
Online ISBN: 978-3-642-18260-0
eBook Packages: Springer Book Archive